thiotepa riemser
esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiska medel - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.
trica 20 mg/ml injektionsvätska, suspension
esteve pharmaceuticals gmbh - triamcinolonhexacetonid - injektionsvätska, suspension - 20 mg/ml - triamcinolonhexacetonid 20 mg aktiv substans; bensylalkohol hjälpämne; sorbitol hjälpämne
lederlon 20 mg/ml injektionsvätska, suspension
ebb medical ab - triamcinolonhexacetonid - injektionsvätska, suspension - 20 mg/ml - sorbitol hjälpämne; bensylalkohol hjälpämne; triamcinolonhexacetonid 20 mg aktiv substans
buprenorphine/naloxone g.l. pharma 8 mg/2 mg resoriblett, sublingual
g.l. pharma gmbh - buprenorfinhydroklorid; naloxonhydrokloriddihydrat - resoriblett, sublingual - 8 mg/2 mg - naloxonhydrokloriddihydrat 2,44 mg aktiv substans; buprenorfinhydroklorid 8,64 mg aktiv substans; laktosmonohydrat hjälpämne; mannitol hjälpämne
buprenorphine/naloxone g.l. pharma 4 mg/1 mg resoriblett, sublingual
g.l. pharma gmbh - buprenorfinhydroklorid; naloxonhydrokloriddihydrat - resoriblett, sublingual - 4 mg/1 mg - mannitol hjälpämne; laktosmonohydrat hjälpämne; naloxonhydrokloriddihydrat 1,22 mg aktiv substans; buprenorfinhydroklorid 4,32 mg aktiv substans
buprenorphine/naloxone g.l. pharma 2 mg/0,5 mg resoriblett, sublingual
g.l. pharma gmbh - buprenorfinhydroklorid; naloxonhydrokloriddihydrat - resoriblett, sublingual - 2 mg/0,5 mg - buprenorfinhydroklorid 2,16 mg aktiv substans; naloxonhydrokloriddihydrat 0,61 mg aktiv substans; laktosmonohydrat hjälpämne; mannitol hjälpämne
candesartan genmed pharma 32 mg tablett
genmed pharma gmbh - kandesartancilexetil - tablett - 32 mg - mannitol hjälpämne; kandesartancilexetil 32 mg aktiv substans; glycerol hjälpämne
candesartan genmed pharma 16 mg tablett
genmed pharma gmbh - kandesartancilexetil - tablett - 16 mg - kandesartancilexetil 16 mg aktiv substans; mannitol hjälpämne; glycerol hjälpämne
candesartan genmed pharma 4 mg tablett
genmed pharma gmbh - kandesartancilexetil - tablett - 4 mg - mannitol hjälpämne; glycerol hjälpämne; kandesartancilexetil 4 mg aktiv substans
piperacillin/tazobactam midas pharma 4 g/0,5 g pulver till infusionsvätska, lösning
midas pharma gmbh - piperacillinnatrium; tazobaktamnatrium - pulver till infusionsvätska, lösning - 4 g/0,5 g - tazobaktamnatrium aktiv substans; piperacillinnatrium aktiv substans - piperacillin och enzymhämmare